Skip to main content

Advertisement

SpringerLink
Log in

Pharma deal making: a bright spot amid the gloom

  • News Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

  • 2 Altmetric

Biopharma M&A is back and IPOs are possible, but most biotechs aren’t out of the woods.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Merger and acquisition activity over time.
Fig. 2: IPO activity over time.
Fig. 3: Licensing activity over time.
Fig. 4: Licensing activity by therapeutic area.

Author information

Authors and Affiliations

  1. London, UK

    Melanie Senior

Authors
  1. Melanie Senior
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Senior, M. Pharma deal making: a bright spot amid the gloom. Nat Biotechnol 41, 1365–1372 (2023). https://doi.org/10.1038/s41587-023-01958-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-023-01958-7

  • Springer Nature America, Inc.

Search

Navigation